TriSalus Life Sciences (TLSI) Retained Earnings (2020 - 2026)

TriSalus Life Sciences has reported Retained Earnings for 7 years, with the latest figure at -$329.0 million in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings fell 13.49% year-over-year to -$329.0 million; the trailing twelve-month figure through Mar 2026 stood at -$329.0 million (down 13.49% YoY), and the FY2025 full-year result was -$330.6 million, down 18.26% from the prior year.
• Retained Earnings for Q1 2026 stood at -$329.0 million, roughly flat from -$330.6 million in the prior quarter.
• The five-year high for Retained Earnings was -$11.5 million in Q2 2022, with the low at -$330.6 million in Q4 2025.
• Historically, Retained Earnings has averaged -$197.6 million across 5 years, with a median of -$261.6 million in 2024.
• Annual changes were most pronounced in 2022 — Retained Earnings soared 46.26% — and 2024, when it sank 1788.1%.
• TriSalus Life Sciences' Retained Earnings stood at -$186.4 million in 2022, then sank by 33.88% to -$249.5 million in 2023, then slipped by 12.04% to -$279.5 million in 2024, then fell by 18.26% to -$330.6 million in 2025, then climbed by 0.47% to -$329.0 million in 2026.
• The last three Retained Earnings figures came in at -$329.0 million (Q1 2026), -$330.6 million (Q4 2025), and -$321.0 million (Q3 2025), per Business Quant data.